For example, DPPIV inhibitor sitagliptin reducing the rate of acute GVHD following allogeneic HSCT suggests an important role in immunosuppression and clinical outcomes of immune-mediated disorders. This evidence concerns the gene DPP4 and acute graft versus host disease.